

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALOXONE)
ANTITRUST LITIGATION**

**MDL NO. 2445
13-MD-2445**

THIS DOCUMENT RELATES TO:

Wisconsin, et al. v. Indivior Inc. et al.
Case No. 16-cv-5073

**STATE OF WISCONSIN
By Attorney General Brad D. Schimel, et al.**

CIV. A. NO. 16-5073

Plaintiffs,

v.

**INDIVIOR INC. f/k/a RECKITT BENCKISER
PHARMACEUTICALS, INC., et al.**

Defendants.

ORDER

AND NOW, this 22nd day of August, 2022, upon consideration of Defendant Indivior Inc.’s Motion for Summary Judgment on All Claims (MDL No. 13-2445, Doc. Nos. 699 and 706; Civ. A. No. 16-5073, Doc. No. 450), Defendant Indivior Inc.’s Motion for Summary Judgment Pertaining to Specific Plaintiffs and Remedies (MDL No. 13-2445, Doc. Nos. 699 and 706), the Direct Purchaser and End Payor Plaintiffs’ Response (MDL No. 13-2445, Doc. Nos. 731, 732, and 734), the Plaintiff States’ Response (Civ. A. No. 16-5073, Doc. Nos. 464, 465), and Indivior’s Reply (MDL No. 13-2445, Doc. No. 740; Civ. A. No. 16-5073, Doc. No. 469), and following oral argument, it is hereby **ORDERED** that both Motions are **DENIED**.

BY THE COURT:

/s/ Mitchell S. Goldberg

MITCHELL S. GOLDBERG, J.